Endometrial Cancer

The phase 3 LEAP-001 trial did not meet its primary end points of overall survival and progression-free survival.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the use of immune checkpoint inhibitors in patients with advanced endometrial cancer. This is the second of 2 articles based on this event.

Selinexor maintenance therapy shows potential in bettering survival compared with placebo in patients with TP53 wild-type recurrent or advanced endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul A. DiSilvestro, MD, discussed with participants concerning the management of adverse events in a patient receiving single-agent immune checkpoint inhibitor for advanced mismatch-repair deficient endometrial cancer.

The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.

An exploratory analysis of Study 309/KEYNOTE-775 showed further benefit for patients and consistent safety in patients who received pembrolizumab plus lenvatinib for advanced endometrial cancer who continued lenvatinib treatment.

Findings from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial showed that patients with dMMR/MSI-H had a progression-free survival rate of 57.0% in the dostarlimab arm vs 10.2% in the placebo arm.

The emergence of preliminary efficacy evidence, and potential biomarker targets, with the combination of the novel anti-TGIT agent etigilimab and nivolumab was presented at the 2023 ESMO Congress.

Adding durvalumab to chemotherapy, followed by durvalumab and olaparib maintenance therapy improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer.

The addition of atezolizumab to chemotherapy improved progression-free survival in frontline advanced or recurrent endometrial carcinoma, in particular, among patients with deficient mismatch repair status.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the importance of mismatch repair deficiency testing and the value of next-generation sequencing in patients with advanced endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rebecca Arend, MD, and participants discussed the use of single-agent immune checkpoint inhibitor as opposed to pembrolizumab plus lenvatinib in a patient with recurrent mismatch-repair deficient endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ritu Salani, MD, MBA, discussed trials supporting the use of the immune checkpoint inhibitors pembrolizumab and dostarlimab in patients with metastatic endometrial cancer.

In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the endometrial cancer landscape and future projections.

A phase 1/2 study of tulmimetostat in patients with advanced solid tumors and lymphomas is underway.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed trials of immune checkpoint inhibition and when to discontinue treatment in patients with endometrial cancer. This is the second of 2 articles based on this event.

Regardless of mismatch repair status, the phase 3 NRG-GY018 trial showed an improvement in progression-free survival when patients with endometrial cancer were given pembrolizumab with chemotherapy.

In an interview with Targeted Oncology, Ruchi Garg, MD, discussed the evolution of the treatment landscape for patients with endometrial cancer and what trials to watch out for in the future.

Patients with hormone receptor-positive endometrial cancer had an objective response rate of 30%, including 8 confirmed responses, when treated with letrozole with abemaciclib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed the treatment options for a patient with endometrial cancer who relapsed following resection and again following a complete response to chemotherapy. This is the first of 2 articles based on this event.

During an interview with Targeted Oncology, Matthew A. Powell, MD, discussed the significance of the FDA approval and his presentation of the results from the RUBY trial.

FDA approval has been granted to dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient and microsatellite instability-high primary advanced or recurrent endometrial cancer.

Results from a subgroup analysis of the phase 3 SIENDO study show a survival advantage, signaling that tp53 may have predictive value for treatment with selinexor, in addition to its prognostic value.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Coleman, MD, discussed the treatment approach for a patient with relapsed endometrial cancer.

Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.

In an interview with Targeted Oncology, BJ Rimel, MD, discussed the rationale, methods, and design of this phase 2 study for patients with endometrial cancer.

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

Expert perspectives on the RUBY and GY018 trials, which tested dostarlimab and pembrolizumab, respectively, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.

According to the developer, a future approval of dostarlimab for this indication would bring the first meaningful frontline treatment for this patient population in decades.

New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.